Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCommunity-Care Pombiliti Prior Auth Coverage | Ope…
    Ask Trek AI about this page
    CurrentCommunity-CarePolicy N/A

    Pombiliti (cipaglucosidase alfa) Medical Benefit Medication Utilization Policy

    Customize your policy alerts

    Sign up for all Community-Care policy alerts

    Know when Community-Care releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical-benefit coverage, prior authorization, quantity limits, and continuation criteria for cipaglucosidase alfa (Pombiliti) used to treat late-onset Pompe disease for members covered by the payer.

    Policy Summary
    PayerCommunity-Care
    PolicyPombiliti (cipaglucosidase alfa) Medical Benefit Medication Utilization Policy
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Last ReviewMar 1, 2024
    Next Review DateN/A
    Key ActionObtain prior authorization with documentation of diagnostic confirmation, prescriber specialty, concomitant miglustat prescription, symptoms/objective signs, and member weight for dosing.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    20 mg/kg q2wmaximum authorized dose and frequency
    1 yearauthorization period if approved
    J1203HCPCS code

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Mar 2024last reviewed

    Coverage Criteria for Pombiliti (cipaglucosidase alfa)

    Initial Therapy

    Covered when ALL of the following are met for initial approval:

    Initial approval - Late-onset Pompe disease: Clinical diagnosis of late-onset Pompe disease confirmed by genetic sequencing OR acid alpha-glucosidase enzyme assay; prescribed by a medical geneticist or neuromuscular specialist; cipaglucosidase alfa is prescribed with miglustat (Opfolda); patient is experiencing symptoms or objective signs of Pompe disease.

    Continuation Therapy

    Covered when ALL of the following are met for continuation:

    Continuation therapy - Late-onset Pompe disease: Diagnosis of late-onset Pompe disease; member is benefiting from therapy, is being monitored, and is appropriate to continue therapy.

    This policy covers cipaglucosidase alfa (Pombiliti) for late-onset Pompe disease only when specific conditions are met. For initial approval, the member must have a clinical diagnosis of late-onset Pompe disease confirmed by genetic sequencing OR an acid alpha-glucosidase enzyme assay, the prescription must come from a medical geneticist or neuromuscular specialist, the enzyme replacement therapy must be co-prescribed with miglustat (Opfolda), and the patient must be experiencing symptoms or objective signs of Pompe disease. These elements must all be documented in the prior authorization request.

    For continuation of therapy, coverage will be approved when the member has an established diagnosis of late-onset Pompe disease and there is documentation that the member is benefiting from therapy, is being monitored, and is appropriate to continue therapy. Requests for ongoing authorization must include evidence of clinical benefit and monitoring consistent with specialist management.

    Initial Therapy — Detailed Criteria

    Initial therapy criteria

    Initial: Clinical diagnosis of late-onset Pompe disease confirmed by genetic sequencing OR acid alpha-glucosidase enzyme assay; prescribed by a medical geneticist or neuromuscular specialist; cipaglucosidase alfa prescribed with miglustat; patient symptomatic or has objective signs.

    Continuation Therapy — Detailed Criteria

    Continuation criteria

    Continuation will be approved when the member demonstrates benefit and appropriate monitoring.

    Continuation: Diagnosis of late-onset Pompe disease AND member is benefiting from therapy, is being monitored, and is appropriate to continue therapy.

    Coding and Dosing Information

    Applicable HCPCS CodeHCPCSCovered
    J1203Injection, cipaglucosidase alfa-atga, 5 mg
    Authorized dosing frequency
    Authorized dosing frequencyUp to 20 mg/kg every 2 weeks (maximum authorized dose and frequency)
    Authorization periodIf approved, coverage is allowed for one year
    HCPCS code for billingJ1203 — Injection, cipaglucosidase alfa-atga, 5 mg

    Quantity Limits and Dosing Requirements

    cipaglucosidase alfa — dosing limit
    Quantity limit (cipaglucosidase alfa)Authorized for quantities of up to 20 mg/kg
    Dosing intervalEvery 2 weeks
    Authorization contextLimit applies when approved for late-onset Pompe disease
    cipaglucosidase alfa — weight required for dose calculation
    Weight requirementA patient weight is required for approval to calculate mg/kg dosing
    Unit for approvalWeight must be provided in kilograms (kg)
    Purpose

    Provider Requirements, Prior Authorization, and Documentation

    Prior Authorization

    Prior authorization required — include diagnostic confirmation, prescriber specialty, miglustat co‑prescription, symptoms, and weight

    Prior authorization is required for cipaglucosidase alfa (J1203). The PA must include documentation confirming the diagnosis (genetic sequencing OR acid alpha‑glucosidase enzyme assay), the prescribing specialist (medical geneticist or neuromuscular specialist), that cipaglucosidase alfa is prescribed with miglustat (Opfolda), evidence of symptoms or objective signs, and the member's weight for dosing.

    • Include diagnostic confirmation by genetic sequencing or acid alpha‑glucosidase enzyme assay.
    • Confirm prescriber specialty: medical geneticist or neuromuscular specialist.
    • Document that miglustat (Opfolda) is co‑prescribed with cipaglucosidase alfa.
    • Provide evidence of symptoms or objective signs of Pompe disease.
    • Provide member weight for dosing calculation (authorization requires weight).
    Note

    Provider action highlights — specialist prescriber, co‑prescription with miglustat, and objective evidence required

    Key Definitions

    Late-onset Pompe disease — diagnostic confirmation
    DefinitionLate-onset Pompe disease: clinical diagnosis confirmed by genetic sequencing OR acid alpha-glucosidase enzyme assay
    Confirmatory tests — option 1Genetic sequencing
    Confirmatory tests — option 2Acid alpha-glucosidase enzyme assay
    Associated policy noteDiagnosis confirmation is required for initial approval and documentation must include one of the above tests

    Clinical Background

    Pompe disease (glycogen storage disease type II) is an inherited deficiency of the lysosomal enzyme acid alpha-glucosidase that leads to progressive accumulation of glycogen in muscle tissue, resulting in progressive skeletal and respiratory muscle weakness. Late-onset Pompe disease typically presents with progressive limb-girdle and respiratory muscle weakness and a variable clinical course. Cipaglucosidase alfa is an enzyme replacement therapy indicated for treatment of late-onset Pompe disease and, per this policy, must be prescribed together with miglustat (Opfolda) when used for this indication.

    Step Therapy Requirements

    StepRequirement
    Step 1Covered when ALL of the following are met for initial approval: (1) Clinical diagnosis of late‑onset Pompe disease confirmed by genetic sequencing OR acid alpha‑glucosidase enzyme assay; (2) Prescribed by a medical geneticist or neuromuscular specialist; (3) Cipaglucosidase alfa is prescribed with miglustat (Opfolda); (4) Patient is experiencing symptoms or objective signs of Pompe disease.

    Site of Care Considerations

    Billing Rule

    Site‑of‑care note — include patient weight; dose authorization tied to weight-based limit

    Site‑of‑care information: authorization includes a weight requirement for approval and quantity limits of up to 20 mg/kg every 2 weeks; include member weight on the PA to support site‑of‑care dosing and authorization.

    • Quantity limit if approved: up to 20 mg/kg every 2 weeks.
    • A weight is required for approval and must be submitted with the authorization request.
    Policy Summary
    PayerCommunity-Care
    PolicyPombiliti (cipaglucosidase alfa) Medical Benefit Medication Utilization Policy
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Last ReviewMar 1, 2024
    Next Review DateN/A
    Key ActionObtain prior authorization with documentation of diagnostic confirmation, prescriber specialty, concomitant miglustat prescription, symptoms/objective signs, and member weight for dosing.
    SourceLink
    On This Page
    Coverage Criteria for Pombiliti (cipaglucosidase alfa)Initial Therapy — Detailed CriteriaContinuation Therapy — Detailed CriteriaCoding and Dosing InformationQuantity Limits and Dosing RequirementsProvider Requirements, Prior Authorization, and DocumentationKey DefinitionsClinical BackgroundStep Therapy RequirementsSite of Care Considerations
    Used to determine authorized quantity (mg/kg) for cipaglucosidase alfa

    Providers must ensure the prescription is written by an appropriate specialist and that miglustat is co‑prescribed; submit objective evidence of disease and the patient's weight with the request to avoid processing delays.

    • Prescription must be from a medical geneticist or neuromuscular specialist.
    • Cipaglucosidase alfa must be prescribed together with miglustat (Opfolda).
    • Provide objective signs or documented symptoms of Pompe disease.
    Documentation Required

    Documentation specifics — diagnostic confirmation, prescriber specialty, prescription details, symptoms, and weight

    Submit documentation confirming late‑onset Pompe disease by genetic sequencing OR acid alpha‑glucosidase enzyme assay, the prescriber's specialty (medical geneticist or neuromuscular specialist), the complete prescription details including co‑prescription of miglustat (Opfolda), evidence of symptoms or objective signs, and the patient's weight for dosing.

    • Diagnostic test result: genetic sequencing OR acid alpha‑glucosidase enzyme assay.
    • Prescriber specialty documented (medical geneticist or neuromuscular specialist).
    • Prescription details showing cipaglucosidase alfa given with miglustat (Opfolda).
    • Clinical documentation of symptoms or objective signs of Pompe disease.
    • Patient weight (required for dosing: up to 20 mg/kg every 2 weeks).
    Denial Risk

    Denial risks — missing diagnostic proof, incorrect prescriber specialty, or no miglustat co‑prescription

    Requests lacking required diagnostic confirmation, not authored by an appropriate specialist, or without documentation that cipaglucosidase alfa is prescribed with miglustat may be denied.

    • Absence of genetic sequencing OR acid alpha‑glucosidase enzyme assay confirming diagnosis.
    • Prescriber is not a medical geneticist or neuromuscular specialist.
    • No documentation that miglustat (Opfolda) is co‑prescribed with cipaglucosidase alfa.
    • Missing evidence of symptoms or objective signs, or missing patient weight for dosing.